Japan-based Chugai pharmaceuticals recently announced that the company plans to invest nearly S$476 million into its research institute in Singapore-Chugai Pharmabody Research (CPR) from now until 2021. The company is to invest this huge amount of money to foster and accelerate research and development of new therapeutic antibodies. The company said in a statement that the additional investment will make the centre, one of the largest pharmaceutical operation in Singapore.
Mr Koichi Matsubara, director and CEO of Chugai pharmaceuticals, said that the research institute also planned to increase its strength by 40 researchers by 2016. The institute currently employs around 70 people with expertise in developing antibody drugs using Chugai innovatory platforms.
Mr Lim Chuan Poh, chairman of A*STAR,Singapore, said that Chugai’s expansion in Singapore shows Singapore’s attractiveness as a biotech hub with ready access to biomedical research talent, state-of-the-art infrastructure, and an environment that encourages open innovation through partnerships.
This article is based on materials provided by: